Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 3,618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Cancer Clear all
Terminated Phase 1 Interventional

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

NCT02012231
View directory record Official record
Conditions
Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Histiocytosis, Hairy Cell Leukemia
Interventions
PLX8394
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 25, 2026, 2:03 AM EDT
Terminated Phase 1 Interventional

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT01233505
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
veliparib, capecitabine, oxaliplatin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

NCT01001377
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Cetuximab, Panitumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
5
States / cities
Stockton, California • Boynton Beach, Florida • Wichita, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 25, 2026, 2:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Elironrasib, Daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Duarte, California • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

NCT02375672
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Pembrolizumab, mFOLFOX6
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

NCT00005639
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Azacitidine Injection, sodium phenylbutyrate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

NCT00054977
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions
GM-CT-01, 5-fluorouracil
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Jacksonville, Florida • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Lidocaine for Oxaliplatin-induced Neuropathy

NCT03254394
View directory record Official record
Conditions
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
Interventions
Lidocaine Hydrochloride, Placebo, FOLFOX regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 25, 2026, 2:03 AM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 25, 2026, 2:03 AM EDT
Not listed Phase 3 Interventional

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

NCT00020605
View directory record Official record
Conditions
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naloxone hydrochloride
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 3 Interventional

SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed

NCT00002551
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2008
U.S. locations
35
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 25, 2026, 2:03 AM EDT
Active, not recruiting Not applicable Interventional

Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)

NCT05056077
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Rectal Cancer, Prostate Cancer, Renal Cell Carcinoma, Kidney Cancer
Interventions
Counseling, Educational Intervention, Health Education, Health Promotion and Education - Direct Text Messaging, Health Promotion and Education - Digital health tool kit, Questionnaires
Other · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 2:03 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Epigenetic Signature for CRC Early Detection

NCT07224854
View directory record Official record
Conditions
Colorectal Cancer (Diagnosis), Non-cancer Controls, DNA Methylation, Cell Free DNA, Early Detection of Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 2:03 AM EDT
Terminated Phase 1 Interventional

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

NCT01116154
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
lenalidomide, vorinostat, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Oct 25, 2026, 2:03 AM EDT
Terminated Phase 1Phase 2 Interventional

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

NCT02102022
View directory record Official record
Conditions
Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer
Interventions
ADI-PEG 20 plus modified FOLFOX6
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 25, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

NCT04515394
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Tepotinib, Cetuximab
Drug · Biological
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Not applicable Interventional Results available

Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)

NCT05686122
View directory record Official record
Conditions
Colorectal Cancer
Interventions
PainPac
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 25, 2026, 2:03 AM EDT
Terminated Phase 1 Interventional

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

NCT03866239
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Obinutuzumab, Atezolizumab, Cibisatamab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 25, 2026, 2:03 AM EDT
Completed No phase listed Observational

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

NCT00003329
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
gene mapping
Genetic
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
32
States / cities
Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 2:03 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Improving Outpatient Colonoscopy Bowel Prep With the Orton Score

NCT04093557
View directory record Official record
Conditions
Colonic Polyp, Colon Cancer
Interventions
Orton Score, Typical Standard of Care
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

NCT04744831
View directory record Official record
Conditions
Advanced Colorectal Cancer
Interventions
DS-8201a 5.4 mg/kg Q3W, DS-8201a 6.4 mg/kg Q3W
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

NCT01312857
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
panitumumab, Randomization to No Panitumumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 25, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

NCT04380337
View directory record Official record
Conditions
Rectal Cancer
Interventions
FOLFOXIRI, FOLFOX regimen, XELOX, IMRT
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 25, 2026, 2:03 AM EDT
Terminated Not applicable Interventional

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

NCT00608595
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 25, 2026, 2:03 AM EDT